NKF Spring Clinical Meetings 2025
Advertisement
Joel Topf spoke with Lazarus Award winner Jeffrey Perl at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke with Connie Rhee at SCM25 about her study on cognitive function with dialysis vs conservative CKD management.
Joel Topf spoke with Bradley Marder of Amgen about gout studies at the NKF Spring Clinical Meetings 2025.
A survey sought insight on nephrologists' practices and perceptions about reproductive care for women with kidney disease.
Joel Topf spoke to Excellence in Transplantation Award winner Jayme Locke at the National Kidney Foundation SCM25.
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
One-year results of the AFFINITY trial of atrasentan to treat proteinuria among patients with IgAN were presented at SCM25.
The National Kidney Foundation (NKF) announced the Spring Clinical Meetings 2025 (SCM25) Outstanding Poster honorees.
Researchers presented results of an interim analysis of a study of finerenone among patients with CKD and type 2 diabetes.
Researchers shared baseline characteristics of patients in the phase 3 VISIONARY trial of sibeprenlimab for IgA nephropathy.
Researchers assessed the burden of cardiovascular-kidney-metabolic (CKM) syndrome using NHANES 2001-2020 data.
Research examined outcomes associated with blood volume monitoring for patients on hemodialysis and hospitalized with HF.
Research compared the effects of sparsentan and irbesartan on proteinuria remission in focal segmental glomerulosclerosis.
A study compared kidney stone formation with the use of chlorthalidone vs hydrochlorothiazide for hypertension.
Research explored kidney outcomes among young patients receiving glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
A study compared the impact of conservative management of CKD vs transition to dialysis on risk for cognitive dysfunction.
Researchers assessed how prescription rates of SGLT2i were affected when DKD risk was predicted by a KidneyIntelX test.
Research examined the efficacy and safety of lumasiran for primary hyperoxaluria type 1 in infants and toddlers.
Dosing calculations for carboplatin made using Cockcroft-Gault creatinine clearance may result in excess dosing.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.